Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma

NCT00609011 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Melanoma

Interventions

DRUG: MPC-6827 + Temozolomide

Sponsor

Myrexis Inc.